tiprankstipranks
Trending News
More News >

Clearmind Medicine enrolls first patient in Phase I/IIa trial for CMND-100

Clearmind Medicine (CMND) announced the enrollment of the first patient in its Phase I/IIa clinical trial for CMND-100, the Company’s proprietary MEAI-based oral drug candidate for the treatment of Alcohol Use Disorder. The first patient was enrolled at Yale School of Medicine’s Department of Psychiatry, marking a significant milestone in the trial. The trial is evaluating the safety, tolerability, and pharmacokinetic profile of CMND-100, with preliminary efficacy assessments to explore its potential in reducing alcohol cravings and consumption. This first-in-human study represents a pivotal step toward developing a groundbreaking treatment for individuals struggling with AUD.

Don’t Miss TipRanks’ Half-Year Sale

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1